family history of diabetes but was abnormal (by an arbitrary standard) in about one-third of those with normal tolerance who had a first-degree relative with diabetes. The results of this test in other hands have been erratic and of questionable significance (West 1960 , Jackson 1961 . Fajans & Conn emphasized from the start that this test was no more than a method of selecting subjects for further study. All the same it is daunting to hear the test described after ten years as 'still in the investigative stage and not ready for general application' (Fajans 1965) .
A very interesting observation is that in a proportion of potential diabetics the fasting serum insulin-like activity is significantly above the mean and there is a sluggish rise after the administration of glucose (Steinke et al. 1963 , Pfeiffer et al. 1961 ). These results suggest some interference with the action of insulin and Vallance-Owen (1964) believes that those who are constituted as 'essential' diabetics inherit a synalbumin antagonist to insulin which may or may not lead to carbohydrate intolerance but can be used as a biochemical marker. It is certainly tempting to assume that from an early age, perhaps from birth, those who are destined to become diabetic are obliged to put out more insulin as a result of some loss of the normal action or release of the hormone either by antagonism, an immune mechanism or a failure of synthesis.
Are detection drives desirable? No doubt many physicians in charge of diabetic clinics have felt that the problems of those who have symptoms provide a sufficient burden without encouraging those who are symptomless to have second thoughts. Moreover, present methods of detection and screening inevitably produce a group of borderline subjects whose future we cannot at present foretell with any confidence. It may seem unfair to sow the seeds of doubt in their minds and disturb their healthy image of themselves. On the other hand a certain number of patients with clinical diabetes will be revealed and will benefit from treatment.
It is essential that all surveys and detection drives should take into account the management of those who are found to be abnormal. Only a physician, using that word in the widest sense, can expound, advise and reassure in a manner which is adapted to each individual subject. Detection of diabetes in the community is useful if it leads to improved health in those in whom asymptomatic diabetes has been found. If nothing could be done about it, the exercise might well cause unwarranted apprehension and anxiety. It is well established, of course, that weight loss can greatly improve sugar tolerance in cases of mild diabetes, but not all asymptomatic diabetics are obese and some may remain diabetic after they have achieved a normal weight.
It is with this group of asymptomatic diabetics of approximately normal weight that I am mainly concerned in this report. The study is based on the thesis that the sulphonylurea drugs, which stimulate endogenous insulin production, may have a curative action at certain early stages of human diabetes, just as they have been shown to have in certain types of experimental diabetes in animals (Loubatieres et al. 1956 , Ashworth & Haist 1956 ). In keeping with this possibility is the fact that long-term therapy with the sulphonylureas in overt diabetics may allow good control of the blood sugar although there has been stepwise reduction in the dose of the sulphonylurea (Stowers & Bewsher 1962) . This tends to occur when the diabetes has been of relatively short duration and even when there has been no associated weight loss to account for the apparent improvement in the diabetes. Histological evidence in human diabetics published by Maclean & Ogilvie in 1959 has shown that hypoplasia of the pancreatic beta cells progresses with time, so that it is to be expected that a drug with betacytotrophic action would have more scope in the early stages of diabetes. Fajans & Conn (1960) have already reported an improvement in the oral glucose tolerance of young mild diabetics on long-term treatment with tolbutamide.
Present Trial
For this study trial subjects were selected who had chemical evidence of diabetes, but no associated symptoms. Since they were by definition asymptomatic (i.e. subclinical), special efforts had to be made to find them. The main reasons for testing individuals found to be suitable for the trial were: Symptomless glycosuria; strong family history of diabetes; mother of baby over 10 lb (4 5 kg) at birth; mother of ten or more children; two or more unexplained 'still-births'; islet hyperplasia of the pancreas of a still-born (not due to Rh incompatibility); excessive weight gain in pregnancy; precocious onset of arterial disease, especially in women.
Such individuals were tested for chemical diabetes using the intravenous glucose tolerance test described by Duncan (1956) and expressing the results numerically as increment indices. Statistical comparison between sequential tests was thus simplified compared with the use of oral glucose tolerance testing. The increment index (I.I.) is the mg/100 ml per minute fall in the increment of blood sugar over the fasting value after the intravenous injection of 25 grams of 50% glucose (mixed with 12,000 units of heparin to inhibit phlebothrombosis). Using the results obtained in normal individuals and diabetics by Duncan (1956 ) Amatuzio et al. (1953 and our own experience, we regard increment indices below 2-46 to indicate definite diabetes and above 2-97 to be normal. Intermediate figures have been regarded as probably diabetic. It is recognized that some adjustment of these figures should be made for age, but accurate information on this point is lacking. All subjects in this trial had an initial increment index below 2-97 and the mean value was in the range of definite diabetes but still with a normal fasting capillary true blood sugar level below 115 mg/100 ml. The increment index has been used rather than the total index or K index because it has been shown to be relatively independent of the amount of glucose injected (Duncan 1956 ) and to be derived from a line giving a better fit to a logarithmic function than is obtained when absolute, rather than increment, blood sugars above the fasting level are used (Medley 1965) .
In the use of sequential tests of glucose tolerance as a measure of changes induced by drugs precautions have to be taken to exclude other factors which would affect the tests. Thus, with two exceptions, subjects have not been included in the trial if their weight exceeded the standard described by Kemsley (1952) by more than 10%, although they were not excluded if the weight increased significantly during the trial. In the two exceptions the initial weight was 11 % and 16% above the Kemsley standard and had not fallen by the time of the follow-up intravenous glucose tolerance test. In general, if subjects were more than 10% above their standard weight when first tested, the test was repeated after adequate weight loss and the subjects were included in the trial only if the increment indices were still abnormal. Subjects were always tested when fully ambulant in view of the known tendency of bed rest to impair glucose tolerance. If the subclinical diabetes was first detected during pregnancy or within forty-eight hours of delivery, the intravenous glucose tolerance test was invariably repeated when the effect of pregnancy had passed, and the subject included in the trial only if the increment index was still abnormal.
The sulphonylurea used in the trial was chlorpropamide. This preparation has the advantage of long biological half life so that it needs to be given only once a day and has been free of toxic sideeffects in the dosage used. The sequential intravenous glucose tolerance tests were performed about three weeks after the chlorpropamide had been temporarily discontinued, because the tests were being done not to measure the hypoglycemic action of the drug but its possible action of inducing hyperplasia of the pancreatic beta cells. Initially the dose of chlorpropamide used was 100 mg daily with breakfast, but with the accumulation of experience it became apparent that older subjects with an increment index below 2-00 would tolerate a larger dose. At present rather over half the 168 subjects included in this report are receiving between 100 and 250 mg chlorpropamide daily.
Results
The overall results are summarized in Table 1 . On the whole, the increment index improved from a figure in the definitely diabetic range to one approaching the normal level. Of the 168 subjects in this study 68 (40-5 %) achieved a normal increment index. The total number in the trial has been broken down according to age and sex to see if any particular group did significantly better or worse than the other groups or the group as a whole. An arbitrary division has been drawn at the age of 35 years, because this would tend to separate the younger individuals who would be less likely than the older ones to react favourably to chlorpropamide if they had overt rather than subclinical diabetes.
The separate results for females and males under 35 years of age are given in Table 2. The males under 35 show a better response than the females of this age group, although the mean improvement in the increment index in the males was so much greater than that of the females largely because of the unusually good response of 2 of the 20 subjects. Nevertheless the picture emerges from all the data that the males appear to show a better response, although the numbers are too small to achieve statistical significance. It is possible that the diabetogenic effect of previous pregnancies may have had a part to play in reducing the responsiveness of the women to longterm chlorpropamide treatment. Table 3 similarly displays the results for the two sexes at ages over 35 years. Here again the men have fended to improve more than the women although their mean age was greater and increasing age is probably an unfavourable factor in the 
responsiveness. The fact that fewer women attained a normal increment index can be explained at least in part by their mean initial increment being 0-16 lower than that of the men. In this age group, of course, the possibility of multiparity affecting the responsiveness of the women may be more important. Another factor may have been a greater tendency for the women to gain weight during the trial. The association between age and the results obtained in the sequential tests is expressed in Table 4 .
Although the proportion who improved was very similar in each age group (75 % and 72 %) the extent of the improvement was markedly better in the under-35s, both when measured as the change in the increment index and as the percentage who achieved a normal increment index. This situation contrasts with the general experience that in symptomatic diabetes those over 35 years of age respond significantly better to sulphonylureas than do younger diabetics. When the increment index had improved from the diabetic well into the normal range in 26 subjects the opportunity was taken to stop the chlorpropamide for a number of months to see how long the improvement was maintained. Seven relapsed to a subnormal increment index after six to eleven months. In the group as a whole the mean increment index fell from 4 30 to 3 79 after a mean interval of 10-4 months. The relapses were about equally distributed between the two age groups.
In view of the encouraging results obtained in long-term therapy for subclinical diabetes with small doses of chlorpropamide it was decided to see if there was any evidence of a curative action of chlorpropamide in overt diabetics who had long been maintained with perfectly normal random blood sugar levels on doses of chlorpropamide, decreasing to 100 to 250 mg daily. Twenty-three diabetics were chosen, ranging in age from 52 to 78 years. They had initially all presented with raised blood sugar levels and diabetic symptoms. None exceeded the normal weight standard by more than 10% when their treatment started. They had been on sulphonylurea treatment for nine and a half to sixty-six months continuously and then were asked to stop it and to return in one week for review. If the blood sugar level was still normal they returned in a further two weeks for an intravenous glucose tolerance test. By the end of the first week off treatment 5 of the 23 had clearly raised random blood sugar levels and were put back on treatment. After a further two weeks off treatment another subject had developed a high fasting blood sugar level and diabetic symptoms, so was again treated with chlorpropamide. Thus 17 subjects remained for intravenous glucose testing. The glucose utilization was extremely poor in all, 11 showing a virtually flat line.
The study left no doubt that this group of diabetics had shown no curative effect of chlorpropamide once the drug had been discontinued. The conclusion to be drawn is that if chlorpropamide is to have a chance to exert an apparently curative effect on glucose intolerance the diabetes must be treated before it becomes overt. The younger subjects appear to respond better than the older ones.
The value of the main observations reported here is limited by the absence of a control group followed up in the same way but given no chlorpropamide treatment. Since November 1963 the Medical & Scientific Section of the British Diabetic Association has been running such a trial on a fairly small scale so that groups of subclinical diabetics are treated at random either by chlorpropamide 100 mg daily or a placebo which appears identical. A harmless marker substance has been added to both sets of tablets so that a check can be made that they are actually being taken. If sequential tests show evidence of significant deterioration in glucose tolerance this is first confirmed and then the individual is removed from the trial and given standard treatment. Evidence of such deterioration has been obtained before the development of any diabetic symptoms. Too few results are available yet from this doubleblind study to be statistically significant.
